An interventional study of Multi-faceted pharmacist-led transition of care (ToC) program in Transitional Care, sponsored by Dr. Muhammad Abdul Hadi. Recruiting at 1 site in Qatar. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-21.
Sponsored by Dr. Muhammad Abdul Hadi · Not applicable, Interventional, and Health services research
When patients leave the emergency department, mistakes with their medications are common and can lead to complications or hospital readmissions. Pharmacists are trained to help prevent these problems, but pharmacist-led transition of care services are not routinely provided in emergency departments.
This study is a small pilot randomized controlled trial designed to see whether a pharmacist-led transition of care program can be carried out successfully in the emergency department at Al-Wakra Hospital. The study will help determine if a larger trial is feasible in the future.
Patients who are being discharged home from the emergency department and meet the study criteria will be invited to participate. Those who agree will be randomly assigned to one of two groups:
Usual care, or Usual care plus the pharmacist-led transition of care program The pharmacist-led program includes reviewing the discharge prescription, checking and updating the medication list, providing medication education, arranging follow-up with a pharmacist-run clinic, communicating with outpatient pharmacists, and following up with the patient after discharge.
The pilot trial will help determine how many patients are eligible, how many agree to participate, how well the intervention can be delivered in the emergency department, and whether patients and staff find it acceptable. The results will be used to plan a larger study that will test whether this program can reduce healthcare use after discharge.
This is the only study on the registry with Dr. Muhammad Abdul Hadi as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in this group will receive standard care in accordance with Hamad Medical Corporation's (HMC) policies and practices. Currently, case review by clinical pharmacists for all ED patients at the study site is not part of routine care. Medication review, reconciliation, discharge education, and follow-up are typically managed by ED-physicians and nurses. Clinical pharmacists may be consulted, depending on availability, for complex or selected cases only. Control group patients will not be denied pharmacist-led TOC services when deemed necessary as part of routine clinical judgment. These instances will be recorded, including the reason, nature, and timing of the care provided by the pharmacist.
Participants receive usual care plus a pharmacist-led transition of care (ToC) program, which includes medication review, reconciliation, discharge counseling, coordination of follow-up, and post-discharge pharmacist visits.
Behavioral: Multi-faceted pharmacist-led transition of care (ToC) program
The pharmacist-led transition of care (ToC) intervention begins once a patient is deemed ready for ED discharge. ED pharmacists conduct a comprehensive discharge medication review, identify and resolve medication therapy problems, and document recommendations in the electronic health record (EHR). They perform discharge medication reconciliation, generate the best possible medication list, and correct any discrepancies. Pharmacists provide structured medication counseling using teach-back and address adherence barriers. Discharge planning includes scheduling post-discharge follow-up in a pharmacist-led medication therapy management clinic and delivering a standardized handover to ambulatory pharmacists. Patients receive two post-discharge follow-up visits within 7 and 14 days, during which pharmacists reassess medications, resolve new or ongoing issues, provide education, and coordinate additional care when needed. All activities follow standardized documentation procedures.
Eligibility rate among screened patients
Proportion of screened emergency department (ED) patients who meet all inclusion criteria and none of the exclusion criteria for the pilot trial.
Time frame: At baseline (Day 1)
Recruitment rate among eligible patients
Proportion of eligible patients who agree to participate, provide informed consent, and are randomized into the trial.
Time frame: At baseline (Day 1)
Retention rate at post-discharge follow-up
Proportion of enrolled patients who: (a) in the intervention group, attend pharmacist-led follow-up visits at 7 and 14 days after ED discharge; and (b) in both groups, complete the 30-day follow-up phone call.
Time frame: Intervention arm: Day 7, Day 14, and Day 30 after ED discharge, Control arm: Day 30 after ED discharge
Intervention fidelity: receipt of all ToC program components
Proportion of participants in the intervention arm who receive all prespecified components of the pharmacist-led transition of care intervention (discharge medication review, discharge medication reconciliation, patient counseling, discharge planning, and post-discharge follow-up).
Time frame: Through day 30 after ED discharge
Proportion of patients with ≥1 unintentional medication discrepancy
Proportion of patients with at least one unintentional medication discrepancy identified by the clinical pharmacist at ED discharge and during post-discharge follow-up visits.
Time frame: Through day 30 after ED discharge
Number and types of unintentional medication discrepancies
Total number, mean number per patient, and types of unintentional medication discrepancies identified by the clinical pharmacist at ED discharge and during post-discharge follow-up visits.
Time frame: Through Day 30 after ED discharge
Proportion of patients with ≥1 medication therapy problem (MTP)
Proportion of patients with at least one medication therapy problem identified by the clinical pharmacist at ED discharge and during post-discharge follow-up visits.
Time frame: Through Day 30 after ED discharge
Number and types of medication therapy problems
Total number, mean number per patient, and types of medication therapy problems identified by the clinical pharmacist at ED discharge and during post-discharge follow-up visits.
Time frame: Through Day 30 after ED discharge
Resolution of medication discrepancies and medication therapy problems
Proportion of identified medication discrepancies and medication therapy problems that are resolved before ED discharge, resolved during post-discharge follow-up, or remain unresolved at the end of follow-up.
Time frame: Through Day 30 after ED discharge
Unplanned healthcare utilization within 30 days
Proportion of patients with a composite outcome of unplanned ED revisit and/or unplanned hospital admission for any acute health problem within 30 days of discharge from the index ED visit. Elective admissions and scheduled outpatient visits are excluded.
Time frame: Through Day 30 after ED discharge
ED revisit or hospital admission related to index ED presentation
Proportion of patients with an ED revisit and/or hospital admission determined to be related to the index ED presentation within 30 days of discharge.
Time frame: Through Day 30 after ED discharge
Medication-related ED visits or hospital admissions
Proportion of patients with medication-related ED revisits and/or hospital admissions within 30 days of discharge, identified using AT-HARM10 screening followed by adjudication by a clinical pharmacist and physician.
Time frame: Through Day 30 after ED discharge
Patient satisfaction with pharmacist-led ToC intervention
Patient satisfaction with pharmacist-led transition of care interventions assessed using the Medication Management Patient Satisfaction Survey (MMPSS).
Time frame: Day 30 after discharge
Plan to share: No — Individual participant data will not be shared outside the study team. Data will be analyzed and reported in aggregate form only, in accordance with institutional and ethical approvals.
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Aug 2026, 6 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.